1. Home
  2. MIRM vs FINV Comparison

MIRM vs FINV Comparison

Compare MIRM & FINV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • FINV
  • Stock Information
  • Founded
  • MIRM 2018
  • FINV 2007
  • Country
  • MIRM United States
  • FINV China
  • Employees
  • MIRM N/A
  • FINV N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • FINV Finance: Consumer Services
  • Sector
  • MIRM Health Care
  • FINV Finance
  • Exchange
  • MIRM Nasdaq
  • FINV Nasdaq
  • Market Cap
  • MIRM 2.2B
  • FINV 2.2B
  • IPO Year
  • MIRM 2019
  • FINV N/A
  • Fundamental
  • Price
  • MIRM $50.34
  • FINV $9.25
  • Analyst Decision
  • MIRM Strong Buy
  • FINV Strong Buy
  • Analyst Count
  • MIRM 12
  • FINV 2
  • Target Price
  • MIRM $63.17
  • FINV $11.55
  • AVG Volume (30 Days)
  • MIRM 397.8K
  • FINV 1.4M
  • Earning Date
  • MIRM 08-06-2025
  • FINV 08-19-2025
  • Dividend Yield
  • MIRM N/A
  • FINV 3.02%
  • EPS Growth
  • MIRM N/A
  • FINV 26.19
  • EPS
  • MIRM N/A
  • FINV 1.37
  • Revenue
  • MIRM $379,251,000.00
  • FINV $1,846,779,164.00
  • Revenue This Year
  • MIRM $35.83
  • FINV $13.72
  • Revenue Next Year
  • MIRM $16.83
  • FINV $11.25
  • P/E Ratio
  • MIRM N/A
  • FINV $6.93
  • Revenue Growth
  • MIRM 69.31
  • FINV 5.40
  • 52 Week Low
  • MIRM $28.56
  • FINV $4.63
  • 52 Week High
  • MIRM $54.23
  • FINV $11.08
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 69.78
  • FINV 60.57
  • Support Level
  • MIRM $48.78
  • FINV $8.88
  • Resistance Level
  • MIRM $50.05
  • FINV $8.99
  • Average True Range (ATR)
  • MIRM 1.64
  • FINV 0.27
  • MACD
  • MIRM 0.39
  • FINV 0.07
  • Stochastic Oscillator
  • MIRM 87.92
  • FINV 66.22

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About FINV FinVolution Group

FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.

Share on Social Networks: